UK markets close in 6 hours 41 minutes

  • FTSE 100

    6,602.96
    -47.92 (-0.72%)
     

  • FTSE 250

    21,123.17
    -173.06 (-0.81%)
     

  • AIM

    1,162.99
    -10.40 (-0.89%)
     

  • GBP/EUR

    1.1585
    -0.0012 (-0.10%)
     

  • GBP/USD

    1.3816
    -0.0078 (-0.56%)
     

  • BTC-GBP

    34,060.39
    -2,612.82 (-7.12%)
     

  • CMC Crypto 200

    941.69
    -45.52 (-4.61%)
     

  • S&P 500

    3,768.47
    -51.25 (-1.34%)
     

  • DOW

    30,924.14
    -345.95 (-1.11%)
     

  • CRUDE OIL

    65.14
    +1.31 (+2.05%)
     

  • GOLD FUTURES

    1,691.00
    -9.70 (-0.57%)
     

  • NIKKEI 225

    28,864.32
    -65.79 (-0.23%)
     

  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     

  • DAX

    13,900.78
    -155.56 (-1.11%)
     

  • CAC 40

    5,769.39
    -61.26 (-1.05%)
     
Ranking:

London retains title of most popular city for work

Despite Brexit and the pandemic, London has held the title for the last eight years

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

Dampskibsselskabet NORDEN A/S

ANNOUNCEMENT NO. 28 - 3 FEBRUARY 2021

In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90/2020.

Kind regards,

Dampskibsselskabet NORDEN A/S

Martin Badsted

CFO

For further information:

Martin Badsted, CFO, tel.: +45 3315 0451

Attachments


Latest stories

  • South African Manufacture of Flour and Grain Mill Products 2021, Featuring Profiles of 18 Key Players - ResearchAndMarkets.com

    The "Manufacture of Flour and Grain Mill Products in South Africa 2021" report has been added to ResearchAndMarkets.com's offering.

  • Designing Stark Compliant Physician Compensation Models - Virtual Webinar Session - ResearchAndMarkets.com

    The "6-Hour Virtual Seminar on Designing Stark Compliant Physician Compensation Models" webinar has been added to ResearchAndMarkets.com's offering.

  • Israeli miniser says has list of Iran-backed targets

    Israel’s defense minister says his country has drawn up plans to strike Iranian targets if Tehran shows signs of nuclear escalation. Benny Gantz told Fox News that Israel is still working on its plans, but “we have them in our hands of course.” The remarks come as President Joe Biden’s administration considers re-joining the 2015 Iran nuclear deal to limit Iran's nuclear program, with some changes to toughen curbs on Tehran's activities.

  • Global Probiotic Cosmetic Products Market Report 2021: Market Size is Expected to Reach $400 Million by 2026, Rising at a CAGR of 11%

    Dublin, March 05, 2021 (GLOBE NEWSWIRE) -- The "Global Probiotic Cosmetic Products Market By Distribution Channel (Hypermarket & Supermarket, Pharmacy & Drug Store, E-commerce and other Distribution Channels), By Product (Skin care and Hair Care), By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The Global Probiotic Cosmetic Products Market size is expected to reach $400 Million by 2026, rising at a market growth of 11% CAGR during the forecast period. Probiotic skincare cosmetic products are considered as beauty products that help in increasing the healing benefits of good microorganisms present in our skin. Such products are also in high demand as they control the natural immune response of the skin and create better skin immunity and resilience. The market of probiotic skincare cosmetic products is witnessing a rising growth graph as these products are really beneficial in maintaining bright skin and aid in preventing issues related to skin.For attaining a competitive advantage over others, the people in this market are always in the pursuit of developing products that are profitable and have a positive impact on consumers. Manufacturers also strive to produce cosmetic products mixed with probiotics and other products to improve the quality of cosmetic products.The increasing adoption of probiotics as dietary supplement, probiotics witness a massive demand in the cosmetics category, hence boosting the growth of the market. These cosmetic products are beneficial and suitable to all skin types and can assist in reducing problems related to eczema, chronic inflammation, rosacea, and acne.The industry has been severely impacted by the global COVID-19 pandemic. Various governments have implemented different measures to contain the spread of virus such as Stay-home policy, lockdown measures, and store closures which caused a severe decline in sales. During the pandemic, one of the major observations is that the sentiment of consumers has shifted more toward basic skincare routines and necessities, thus reducing the demand for the probiotic products. Also, the present situation has encouraged customers to step back and choose mass skincare products, which are significantly cheaper and extensively available across all distribution channels.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Estee Lauder Companies, Inc., L'Oreal Group, Unilever PLC, The Clorox Company, Health and Happiness (H&H) International Holdings Limited (Aurelia Probiotic Skincare), Esse Skincare, Tula Life, Inc., Eminence Organic Skin Care, Glowbiotics, Inc., and LaFlore Probiotic Skincare. Key Topics Covered: Chapter 1. Market Scope & Methodology1.1 Market Definition1.2 Objectives1.3 Market Scope1.4 Segmentation1.4.1 Global Probiotic Cosmetic Products Market, by Distribution Channel1.4.2 Global Probiotic Cosmetic Products Market, by Product1.4.3 Global Probiotic Cosmetic Products Market, by Geography1.5 Methodology for the researchChapter 2. Market Overview2.1 Introduction2.1.1 Overview2.1.2 Market composition and scenario2.2 Key Factors Impacting the Market2.2.1 Market Drivers2.2.2 Market RestraintsChapter 3. Global Probiotic Cosmetic Products Market by Distribution Channel3.1 Global Hypermarket & Supermarket Market by Region3.2 Global Pharmacy & Drug Store Market by Region3.3 Global E-commerce Market by Region3.4 Global Other Distribution Channels Market by RegionChapter 4. Global Probiotic Cosmetic Products Market by Product4.1 Global Skin care Market by Region4.2 Global Hair care Market by RegionChapter 5. Global Probiotic Cosmetic Products Market by RegionChapter 6. Company Profiles6.1 Company Overview6.2 Financial Analysis6.3 Regional Analysis6.4 Research & Development Expense6.5 Recent strategies and developments:6.5.1 Partnerships, Collaborations, and Agreements6.5.2 Product Launches and Product Expansions Estee Lauder Companies, Inc.L'Oreal GroupUnilever PLCThe Clorox CompanyHealth and Happiness (H&H) International Holdings Limited (Aurelia Probiotic Skincare)Esse SkincareTula Life, Inc.Eminence Organic Skin CareGlowbiotics, Inc.LaFlore Probiotic Skincare For more information about this report visit https://www.researchandmarkets.com/r/wr9vgx CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • LSE Slides as Refinitiv Costs Overshadow Confident Outlook

    (Bloomberg) -- London Stock Exchange Group Plc said it will spend more on its integration with Refinitiv this year, disappointing analysts and sending its shares falling. Capital expenditure is expected to be about 850 million pounds ($1.2 billion) in 2021, with 150 million pounds of associated operating costs, according to a statement Friday.That overshadowed the company’s confident outlook as it increased its full-year dividend by 7% for 2020. Shares dropped as much as 6.4% in London.Revenue rose to 2.1 billion pounds ($2.9 billion) in 2020 and the company proposed a final dividend of 51.7 pence a share. The group said its recently completed acquisition of Refinitiv left it well-positioned to navigate the challenges of the pandemic and Brexit.“LSEG is now truly global with a significant presence in North America, Europe, Asia and emerging markets,” Chief Executive Officer David Schwimmer said in the statement. The group “is well positioned for long-term sustainable growth.”The stock exchange completed its $27 billion purchase of Refinitiv earlier this year, kicking off a new era where the majority of its revenues come from data. Schwimmer said in a call with journalists that he expects the combination to result in some job cuts and a reduction in some of its real estate footprint.The combined company will generate about 70% of revenues from data, up from 40%, according to Bloomberg Intelligence. The parent company of Bloomberg News competes with Refinitiv to provide financial news, data and information.Schwimmer said LSEG was well-positioned to handle continuing uncertainties around how Brexit might impact the City of London.LSEG’s clearing unit remains a critical element of the European Union’s financial infrastructure even after the U.K. left the bloc. EU politicians have been vocal in demanding that companies shift euro clearing out of London and into the 27-nation bloc. They have achieved some success, with Eurex in Frankfurt increasing its share of euro clearing.Clearing VolumesSo far, though, Schwimmer said the company has seen “no discernible change” in its LCH clearing business, which can continue to service clients in the European Union through June 2022 under the bloc’s temporary rules.“Volumes continue to be very strong and if anything growing,” Schwimmer said in an interview with Bloomberg Television Friday.While London lost its crown to Amsterdam this year as the top place in Europe to buy and sell stock, the shift has had little impact on the group itself, with trades previously done on the company’s U.K. venues largely moving over to its Dutch platform.Schwimmer also welcomed proposals from a review of London’s listings rules, saying recommendations unveiled this week including on special purpose acquisition companies, or SPACs, should be adopted quickly to help London maintain its prime position.“No question, London remains one of world’s leading financial capitals,” Schwimmer said.(Updates with details throughout.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • 9 Bollywood celebrities and their lesser-known partners

    Here are some of the wonderful actors you seldom see in public with their significant others.

  • Dimensional Fund Advisors Ltd. : Form 8.3 - WILLIAM HILL PLC - Ordinary Shares

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree William Hill plc(GB0031698896)(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 4 March 2021(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” N/A If YES, specify which: 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 10p Ordinary Shares Interests Short positions Number % Number %(1) Relevant securities owned and/or controlled: 15,253,965* 1.45% (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 15,253,965 1.45% *Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 159,718 shares. All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unitOrdinary shares Sale 189,562 GBP 2.7090 (b) Cash-settled derivative transactions Class of relevant security Product descriptione.g. CFD Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Typee.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product descriptione.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealinge.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 5 March 2021 Contact name: Thomas HoneTelephone number: 020 3033 3419 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

  • ‘It was not a gift’: Dele Alli ‘deserved to start’ against Fulham, Jose Mourinho insists

    The 24-year-old midfielder made his first start in the Premier League for six months

  • 2021 Spain Gift Card and Incentive Card Market Intelligence and Future Growth: Spend Analysis by Digital/e-Gift Card, Top Retailers, Distribution Channel, Occasions and Demographics - ResearchAndMarkets.com

    The "Spain Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook): Spend Analysis by Digital/e-Gift Card, Retail & Corporate Consumers, Top Retailers, Distribution Channel, Occasions, and Demographics - Jan 2021 Update" report has been added to ResearchAndMarkets.com's offering.

  • Dimensional Fund Advisors Ltd. : Form 8.3 - ARROW GLOBAL GROUP PLC - Ordinary Shares

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Arrow Global Group plc(GB00BDGTXM47)(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 4 March 2021(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” N/A If YES, specify which: 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 1p Ordinary Shares Interests Short positions Number % Number %(1) Relevant securities owned and/or controlled: 3,242,805* 1.83% (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 3,242,805 1.83% *Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 67,304 shares. All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unitOrdinary shares Sale 3,771 GBP 2.6721 (b) Cash-settled derivative transactions Class of relevant security Product descriptione.g. CFD Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Typee.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product descriptione.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealinge.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 5 March 2021 Contact name: Thomas HoneTelephone number: 020 3033 3419 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

  • EU taking ‘very belligerent approach’ to issues caused by NI Protocol – Foster

    Northern Ireland First Minister Arlene Foster said the UK had to take action.

  • United States Faster and Real-time Payments Market Report 2021: Pace of Adoption Accelerated in the U.S. During 2020

    Dublin, March 05, 2021 (GLOBE NEWSWIRE) -- The "U.S. Faster Payments Forecast: The Volume Begins to Build" report has been added to ResearchAndMarkets.com's offering. The pace of real-time and faster payments adoption accelerated in the U.S. during 2020 as explored in new research, U.S. Faster Payments Forecast: The Volume Begins to Build. Solutions such as debit push payments, The Clearing House RTP network, Same Day ACH, and Zelle all experienced strong double-digit and even triple-digit growth in certain use cases. Gains were in part due to the unique environment created by the global pandemic which values fast digital payment types, plus the simple fact that financial institutions and fintechs alike continued to integrate and launch new payment options for customers and members. "More financial institutions completed technical integrations with faster and real-time networks, not only driving transactions from their customers and members for these products, but also beginning to drive internal efficiencies leveraging the new payment rails for account transfers, vendor payments, or payments from clients for loans and credit cards. Faster and real-time payments came to the rescue during the global pandemic, providing more convenient P2P transactions and opportunities including same day settlement for smaller retailers who appreciated receiving their merchant settlement more quickly," comments Sarah Grotta, Director, Debit and Alternative Products Advisory Service. Highlights of the report include: A view into the current state of progression for The Clearing House RTP system, Early Warning's Zelle network, the global debit networks' push payments and Same Day ACHA forecast for dollar volumes processed for each of the networksDiscussion of some of the misnomers and myths circulating about faster and real-time paymentsCurrent use cases where faster payments are succeedingWhere the next wave of faster payments growth is likely to emerge Key Topics Covered: Executive Summary Introduction A DefinitionDispelling Some Myths Where the Market is Growing Now on Available Networks FedNow Debit Card Network Push Payments RTPSame Day ACHZelle Conclusion: Three Key Drivers that Will Power the Next Wave of Growth References Related ResearchEndnotes For more information about this report visit https://www.researchandmarkets.com/r/exvv9z CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Claressa Shields says only Muhammad Ali was greater as she prepares for Marie-Eve Dicaire undisputed clash

    Claressa Shields is in confident mood as she looks to make more boxing history on Friday night. The highly-decorated two-time Olympic gold medalist battles women’s IBF light-middleweight title-holder Marie-Eve Dicaire of Canada in her hometown of Flint, Michigan. Having previously achieved the feat at middleweight, Shields is now seeking to become an undisputed world champion in a second weight division as she also puts her WBC and WBO belts on the line as well as competing for the vacant WBA (Super) and The Ring titles.

  • Improving Cash Cycle Management Is a Key to Corporate Stability: Post-pandemic Economic Outlook in Global Markets by Region - ResearchAndMarkets.com

    The "Improving Cash Cycle Management Is a Key to Corporate Stability" report has been added to ResearchAndMarkets.com's offering.

  • Bolsonaro tells Brazilians to ‘stop whining’ after daily record Covid death toll

    Comments come as Brazil’s health system on the ‘verge of collapse’

  • Japan Women's Beauty Supplements Market Outlook 2021-2027 With Covid-19 Impact - ResearchAndMarkets.com

    The "2021 Women's Beauty Supplements Market With Covid-19 Impact: Japan" report has been added to ResearchAndMarkets.com's offering.

  • London Stock Exchange shrugs off threat from Amsterdam

    LONDON Stock Exchange boss David Schwimmer today shrugged off the threat from Amsterdam, insisting the capital will remain at the centre of global finance. Last month the Dutch passed London as the largest share trading centre for EU denominated shares, a direct consequence of Brexit. Unveiling a 5% rise in annual profits to £1.18 billion, the former Goldman Sachs man, said the shift to Amsterdam was expected and “not meaningful” in terms of the LSE’s business.

  • Japan's 'Wind Phone' offers solace to those grieving

    A white telephone box in a remote village of Japan has become an unlikely source of comfort for those grieving loved ones.Survivors of the 2011 Fukushima disaster say the unconnected phone line helps them keep in touch with those they have lost.Kazuyoshi Sasaki visits the booth in the town of Otsuchi to speak to his late wife.She was one of nearly 20,000 people in northeastern Japan who were killed by the earthquake and tsunami that struck on March 11, 2011.Dialling her now defunct cell, he breaks down in tears as he explains to her how he searched for her for days after the disaster.He goes onto update her on things that have happened in his life - he's moved out of temporary housing, their son is building him a house, and he's lost a bit of weight.For Sasaki, the phone booth is a source of solace:"This phone booth embraces all of me. It embraces various people like the people affected (from the earthquake and tsunami). It's a place that embraces not only the people who are alive but also those who had passed away. That's how I feel."Sachiko Okawa uses the phone to call her late husband, who she was married to for 44 years.She asks him what he's been doing since he was swept away all those years ago in the Tsunami.She often brings along her two grandsons so they can also talk to their grandfather.The phone now attracts thousands of visitors from all over Japan. It is not only used by tsunami survivors, but also by people who have lost relatives to sickness and suicide. Known as the wind phone, it was built by Itaru Sasaki, who created it after he lost his own cousin to cancer a year before the Fukushima disaster.

  • ‘End travel ban earlier,’ demands Labour MP as Cyprus opens fast track for vaccinated Britons

    At present the government has banned all holidays from the UK before 17 May at the earliest

  • Global $18.3 Billion Wearable Injectors Markets, 2021-2028

    Dublin, March 05, 2021 (GLOBE NEWSWIRE) -- The "Wearable Injectors Market Size, Share & Trends Analysis Report by Type (On-body, Off-body), by Technology (Spring-based, Motor-driven), by Application (Oncology, Autoimmune Diseases), by End Use, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global wearable injectors market size is expected to reach USD 18.3 billion by 2028. It is expected to expand at a CAGR of 17.2% from 2021 to 2028. Wearable injectors are drug administration devices designed to deliver drugs in large volumes subcutaneously. It is gaining popularity owing to its advantages such as reduced pain, ease of administration, and elimination of costly health facility visits.Over the last decade, patient interest in the self-administration of injectable drug therapies has grown. The increasing prevalence of diabetes, chronic pain, and auto-immune diseases, such as rheumatoid arthritis, is increasing the use of wearable injectors. Their demand is increasing for the long-term management of asthma, chronic obstructive pulmonary disease (COPD), high cholesterol, and cancer. This is expected to create a lucrative opportunity for advanced device manufacturers to make wearable devices used to administer larger dose volumes at the comfort of home.The recent COVID-19 pandemic has brought remote care technologies, such as wearable injectors, into the spotlight. Demand for chronic disease products remains largely unaffected by the pandemic. Since wearable injectors serve with the option of delivering medications at home, its demand has also remained stable or rather grown for the short term. Patients suffering from chronic diseases are opting for these devices as it reduces the risk of exposure to COVID-19 by eliminating hospital visits. The pandemic has, however, affected some of the devices in the pipeline, affecting short-term investments. Leading players who continue to invest in innovation push projects forward despite COVID-19 are expected to put their companies in a stronger competitive position post-crisis.Wearable Injectors Market Report Highlights By type, the on-body segment led the market in 2020 owing to its advantage to be worn on the skin.The spring-based technology segment held the largest share of 36.3% in 2020 due to a rise in demand for adhesive patches for the treatment of chronic conditions, such as cancer and diabetes.The home care end-use segment led the market in 2020. This can be attributed to a rise in preference for self-administration, especially during the COVID-19 pandemic.North America dominated the market with a share of 41.5% in 2020 owing to the rising prevalence of chronic diseases. Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. Wearable Injectors Market Variables, Trends & Scope3.1. Penetration & Growth Prospect Mapping3.2. Industry Value Chain Analysis3.2.1. Reimbursement framework3.3. Market Dynamics3.3.1. Market driver analysis3.3.2. Market restraint analysis3.3.3. Industry challenges3.4. Wearable Injectors Market Analysis Tools3.4.1. Industry Analysis-Porter's3.4.2. PESTEL Analysis3.4.3. Major Deals & Strategic Alliances Analysis3.4.4. Market Entry StrategiesChapter 4. Wearable Injectors Market: Type Estimates & Trend Analysis4.1. Segment Dashboard4.2. Definitions and Scope4.3. Wearable Injectors Market Share, 2020 & 20284.4. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following4.4.1. On-body4.4.2. Off-bodyChapter 5. Wearable Injectors Market: Technology Estimates & Trend Analysis5.1. Segment Dashboard5.2. Definitions and Scope5.3. Wearable Injectors Market Share, 2020 & 20285.4. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following5.4.1. Spring-based5.4.2. Motor-driven5.4.3. Rotary Pump5.4.4. Expanding Battery5.4.5. OthersChapter 6. Wearable Injectors Market: Application Estimates & Trend Analysis6.1. Segment Dashboard6.2. Definitions and Scope6.3. Wearable Injectors Market Share, 2020 & 20286.4. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following6.4.1. Oncology6.4.2. Infectious Diseases6.4.3. Cardiovascular Diseases6.4.4. Autoimmune Diseases6.4.5. OthersChapter 7. Wearable Injectors Market: End-use Estimates & Trend Analysis7.1. Segment Dashboard7.2. Definitions and Scope7.3. Wearable Injectors Market Share, 2020 & 20287.4. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following7.4.1. Hospitals7.4.2. Clinics7.4.3. Home Care7.4.4. OthersChapter 8. Wearable Injectors: Regional Estimates & Trend Analysis8.1. Regional Market Dashboard8.2. Regional Market Share Analysis, 2020 & 20288.3. Regional Market Share, 2020Chapter 9. Competitive Landscape9.1. Recent Developments & Impact Analysis, By Key Market Participants9.1.1. Company overview9.1.2. Financial performance9.1.3. Product benchmarking9.1.4. Strategic initiatives Becton, Dickinson and CompanyJohnson & Johnson Services, Inc.F. Hoffmann-La Roche Ltd.Unilife CorporationSteadyMed Therapeutics, Inc.Amgen Inc.Insulet CorporationEnable InjectionsWest Pharmaceutical Services, Inc.CeQur SA For more information about this report visit https://www.researchandmarkets.com/r/b3ts7w CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900